Brentuximab vedotin shows extended survival in Hodgkin lymphoma patients

12/16/2013 | Healio (free registration)

Brentuximab vedotin, an antibody drug conjugate that binds to the protein CD30, showed promising benefits in a midstage trial involving 102 patients with Hodgkin lymphoma who received autologous stem cell transplants. About 10% of the study participants achieved long-term remission, raising the possibility that the drug may be curative for a subset of patients, said the University of Washington's Dr. Ajay Gopal.

View Full Article in:

Healio (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN